Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label imaging study of Sonelokimab in psoriatic arthritis and axial spondyloarthritis
2024-514504-13-00Phase 2Authorised
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Mar 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonelokimab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 cohorts), sponsored by MoonLake Immunotherapeutics. Primary endpoint: Change from baseline in 68Ga-FAPI SUVmax signal per lesion at Week 12. Planned start Mar 2025; status: authorised.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2024-514504-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514504-13-00.